Non-alcoholic Steatohepatitis Clinical Trial
Official title:
Investigation of Pharmacokinetics Following Administration of NNC0194-0499 and Semaglutide as Co-formulation Versus Separate Injections in Healthy Participants
Novo Nordisk is developing a combination of 2 medicines (NNC0194-0499 and semaglutide) for the treatment of nonalcoholic steatohepatitis (NASH). NASH is a serious disease where fat, inflammation and scar tissue builds up in the liver. NNC0194-0499 is a new medicine which works in the liver. Semaglutide is a well-known medicine, which is already used to treat type 2 diabetes and obesity. The study is being done to see how 2 medicines (NNC0194-0499 and semaglutide) are absorbed, transported, and eliminated from the body in a combination formulation. Participants will either get NNC0194-0499 and semaglutide in a combination formulation or the separate formulations. Which treatment participants get is decided by chance. The study will last for either 13 or 33 weeks. The duration is decided by chance.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05945537 -
A Study of INI-822 in Healthy Volunteers and Participants With Non-alcoholic Steatohepatitis (NASH) or Presumed NASH
|
Phase 1 | |
| Recruiting |
NCT05462353 -
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH
|
Phase 2 | |
| Recruiting |
NCT05065593 -
The Effect of Aerobic and Resistant Exercise Training in Patients With Non-Alcoholic Steatohepatitis
|
N/A | |
| Terminated |
NCT04171765 -
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
|
Phase 2 | |
| Recruiting |
NCT04365855 -
The Olmsted NAFLD Epidemiology Study (TONES)
|
N/A | |
| Active, not recruiting |
NCT02912260 -
Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
|
Phase 2 | |
| Recruiting |
NCT06054815 -
Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH
|
Phase 2 | |
| Completed |
NCT02784444 -
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
|
Phase 2 | |
| Not yet recruiting |
NCT06160271 -
Study of Liver Fibrosis Stage Assessment by Fibroblast Activation Protein Imaging in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis
|
Phase 2 | |
| Active, not recruiting |
NCT05573204 -
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients With Non-alcoholic Steatohepatitis
|
Phase 2 | |
| Completed |
NCT04042142 -
Glucagon Resistance in Patients With NAFLD
|
N/A | |
| Completed |
NCT04657523 -
Ultrasound-Based Liver Fat Quantification (LFQ) Pilot Study
|
N/A | |
| Completed |
NCT04142424 -
A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects
|
Phase 1 | |
| Terminated |
NCT02787304 -
Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)
|
Phase 2 | |
| Recruiting |
NCT04666402 -
Integrated Diagnostics for Early Diagnosis of Liver Disease
|
||
| Completed |
NCT02528305 -
The Effect of HIT in Patients With Non-alcoholic Fatty Liver Disease/Steatohepatitis
|
N/A | |
| Recruiting |
NCT01056133 -
Effect of Fish-oil on Non-alcoholic Steatohepatitis (NASH)
|
Phase 2 | |
| Completed |
NCT02960204 -
Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension
|
Phase 2 | |
| Completed |
NCT04806750 -
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
|
Phase 2 | |
| Recruiting |
NCT05751720 -
Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue
|
Phase 1/Phase 2 |